Samantha Kingsbury

Mintz

+ Follow Contact

Latest Posts › Generic Drugs

Share:

Federal Trade Commission Announces Workshop on Competition in the Prescription Drug Market

On November 8, 2017, the Federal Trade Commission (FTC) will hold a workshop entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K. Ohlhausen and...more

10/9/2017 / Biosimilars , Competition , Federal Trade Commission (FTC) , Food and Drug Administration (FDA) , Generic Drugs , Hatch-Waxman , Prescription Drugs , Public Meetings , Trade Policy

Federal Judge Awards Attorneys’ Fees to Defendant in Dismissed Qui Tam Case, Calls Whistleblower a “Serial Relator”

In November 2013 and this past October, Mintz Levin’s Health Care Qui Tam Update highlighted three separate qui tam False Claims Act (FCA) cases filed by Fox RX, Inc. (Fox), a former Medicare Part D plan sponsor. Fox filed...more

12/8/2014 / Dismissals , False Claims Act (FCA) , Generic Drugs , Medicare Part D , Omnicare , Qui Tam , Whistleblowers

2 Results

View per page

Page: of 1

Samantha Kingsbury

Mintz

Popular Topics by This Author

Latest Posts › Generic Drugs

Federal Trade Commission Announces Workshop on Competition in the Prescription Drug Market

Federal Judge Awards Attorneys’ Fees to Defendant in Dismissed Qui Tam Case, Calls Whistleblower a “Serial Relator”

"My best business intelligence, in one easy email…"